GSK CEO Chris Viehbacher

A $5 million retention bonus apparently wasn't enough to keep Chris Viehbacher at GlaxoSmithKline. One of the three top GSK execs in the race to succeed Jean-Pierre Garnier (photo) as CEO, Viehbacher was passed over in favor of Andrew Witty (photo), who took over officially after the company's annual meeting this spring. Viehbacher resigned his board seat effective immediately, and he'll leave the company altogether December 1.

Related Articles:
What will Viehbacher bring to Sanofi?
GSK's Viehbacher picked as Sanofi CEO
GSK shuffles execs in operations overhaul
GSK runners-up get $4M, board seat
GSK CEO also-rans may get on board
At GSK, a public race for the top spot